Introduction
Although CD154 was initially recognized for its pivotal role in humoral responses, multiple lines of evidence now support its implication in various immune and infl am matory conditions such as rheumatoid arthritis (RA). CD154 activates numerous cells of critical importance in the pathogenesis of RA, inducing responses such as cytokine release, matrix degradation and autoantibody production, all of which promote disease development [1] . Furthermore, CD154 mediates infl ammatory events through its action on various vascular cells, leading to atherogenesis initiation and progression [2] .
Interestingly, cardiovascular complications such as atherosclerosis and its clinical sequelae have increasingly been associated with autoimmune diseases. Indeed, RA patients exhibit increased morbidity and mortality rates, which are associated with cardiovascular events such as acute coronary syndromes originating from atherosclerotic complications [3] . Overwhelming evidence now highlights the importance of infl ammatory pathways in the pathogenesis of atherosclerosis, thereby supporting that both these diseases share common etiological compo nents [4] . Given its contribution to the pathophysiology of autoimmune diseases and atherosclerosis, CD154 may represent the biological link between both of these disorders as an important risk factor in the development of accelerated vascular complications described in RA patients [5] .
In this review we illustrate the role of CD154 in RA and atherosclerosis, while highlighting its potential implication in the increased vascular events associated with auto immune conditions. We also discuss other traditional or disease-related factors contributing to atherosclerotic events in RA patients.
Structure and function of CD154 and its specifi c receptors
CD154 CD154, also known as CD40 ligand, is a member of the TNF superfamily initially described on T cells [6] but also found on platelets, monocytes and dendritic cells, as well as nonhematopoietic cells including endothelial cells, smooth muscle cells, fi broblasts and others. CD154 was originally shown to play a signifi cantly role in T-depen dent B-lymphocyte responses [7] . In addition to its key role in humoral immunity, CD154 also mediates a vast array of infl ammatory pathways, as evident by its involve ment in cellular immunity. Th ese include priming and expansion of T cells and the activation of antigen-present ing cells and other vascular cells, whereby CD154 was shown to upregulate costimulatory molecules and cytokine production [8] . Th ese cellular events are also the main mechanisms by Abstract Atherosclerosis, now regarded as a chronic infl ammatory disease of the arterial wall, and its clinical manifestations have increasingly been associated with rheumatoid arthritis (RA), supporting the notion that autoimmune diseases and vascular disorders share common etiological features. Indeed, evidence pertaining to this matter indicates that infl ammation and its multiple components are the driving force behind the pathogenesis of these disorders. Interestingly, CD154 and its receptors have emerged as major players in the development of RA and atherosclerosis, which raises the possibility that this axis may represent an important biological link between both complications. Indeed, CD154 signaling elicits critical infl ammatory responses that are common to the pathogenesis of both diseases. Here, we provide an overview of the traditional and disease-related interrelations between RA and vascular abnormalities, while focusing on CD154 as a potential mediator in the development of atherosclerotic events in RA patients.
which CD154 regulates numerous infl ammatory disorders, including RA and vascular diseases.
CD154 receptors CD40
CD40, a glycoprotein from the TNF receptor family, is the classical high-affi nity receptor for CD154. CD40 is constitutively or inducibly expressed by most cells of the vascular and immune system (hematopoietic cells and nonhematopoietic cells) and represents the main signaling molecule in the CD154/CD40 receptor-ligand pair [8] . Th is interaction is required for immunoglobulin isotype switching during the immune response. In fact, patients suff ering from the X-linked hyperimmuno globulin-M syndrome, which results from a genetic mutation in the CD154 gene, fail to produce the immuno globulins IgG, IgA and IgE as a consequence of defi cient CD40 signaling in B cells [9] . Indeed, during humoral immunity, a tight interplay between dendritic cells, T lymphocytes and B lymphocytes occurs, throughout which the activation of CD40 provides a crucial signal for the activation, diff er entiation and secretion of immuno globulins by B cells [10] .
In addition to its pivotal role in adaptive immunity, CD40 ligation generally leads to cell survival and inhibition of apoptosis, critical features of infl ammatory cell resistance and exacerbation during CD154-mediated autoimmune and vascular diseases. Th ese responses are mainly dependent upon the activation of the anti-apoptotic proteins Bcl-XL, A20, Bfl -1 and Mcl-1, which protect against Fas ligand and TNF-induced cell death [11] . CD40 signaling also plays an important role in cell-mediated immunity, through its involvement in the upregulation of a plethora of proinfl ammatory adhesion molecules, cytokines, chemokines, matrix metallo protein ases (MMPs) and procoagulants. For instance, CD40 ligation on synovial cells induces TNFα and IL-1β production, critical infl ammatory mediators of RA patho genesis [12] .
Th e CD154/CD40 axis also regulates the expression and activation of MMP-1, MMP-9 and MMP-3 on monocytes, which contribute to a deleterious degradative cycle in RA [13, 14] . Th rough these infl ammatory pathways, and multiple others, CD40 signaling has been linked to RA development. Indeed, CD154/CD40 signaling plays a critical role in the initiation and progression of the mouse collagen-induced arthritis model, as demonstrated by both pharmacological and genetic approaches (this aspect is also discussed in further detail below) [15, 16] . Moreover, CD40 activation on endothelial cells triggers the release of various infl ammatory mediators of critical importance in the initiation and development of vascular disorders such as atherosclerosis [17] .
Although most vascular and immune complications associated with CD154 have been largely attributed to its interaction with CD40, recently identifi ed additional receptors merit attention. Th ese include the integrins αIIbβ3, α5β1 and αMβ2 ( Figure 1 ).
αIIbβ
Th e αIIbβ3 integrin is abundantly expressed on the surface of platelets and mediates platelet aggregation and adhesion. Binding to its natural ligands, such as fi brinogen, is dependent upon inside-out-mediated conformational activation of the molecule, a phenomenon shared by all members of the integrin family. Interestingly, a KGD sequence can be found within the extracellular domain of the CD154 molecule, thereby allowing binding to the KGD recognition motif of αIIbβ3.
Binding of CD154 to αIIbβ3 was shown to induce phosphorylation of tyrosine residues within the cytoplasmic domain of the β3 subunit and appears essential for thrombus stabilization in vivo [18, 19] . Indeed, CD154 -/mice exhibit unstable thrombi, which can be overcome by infusion of wildtype recombinant human CD154 and not CD154 specifi cally mutated at the site of interaction with αIIbβ3 [18] . Th ese results highlight the importance of the CD154/αIIbβ3 interaction in platelet function and thrombus formation, although additional studies are needed to further consolidate the implication of this new dyad in thromboinfl ammatory reactions.
α5β1
Th e fi bronectin α5β1 integrin receptor was also shown to bind CD154 [20] . Cells of the undiff erentiated human monocytic U937 cell line can interact with soluble CD154 (sCD154) in a CD40-independent and αIIbβ3-independent manner. Binding appears to be mediated by α5β1, since preincubation with anti-α5β1 antibodies or soluble α5β1 reverses the interaction of sCD154 to this cell line. Interest ingly, CD154 can interact with both CD40 and α5β1 concomitantly, as co-incubation of sCD154 with soluble CD40 does not aff ect binding to α5β1, indicating that CD40 and α5β1 share distinct binding residues for CD154 [20, 21] .
Unlike αIIbβ3, CD154 interacts with constitutively inactive α5β1, which is uncommon to the classical scheme of integrin outside-in signaling and activation. Th is observation was demonstrated by experiments in which activation of α5β1 by chemical agents such as DTT hinders the binding to sCD154. Moreover, bronchial fi bro blasts obtained from asthmatic subjects have been previously shown to interact with CD154 from T cells in a α5β1-dependent manner, suggesting the existence of CD154/α5β1 cross-talk in infl ammatory airway diseases such as asthma [22] . Nevertheless, the physiological relevance of this interaction remains unexplored and additional studies are needed to fully characterize the exact contribution of this novel CD154 binding partner in infl ammatory disorders.
αMβ2
Th e αMβ2 (Mac-1) integrin mediates fi rm adhesion of leukocytes to infl amed vessels by interacting with its endothelial cell counter-receptor intercellular adhesion molecule-1. CD154 is also able to interact with this integrin, and this interaction may represent an alternative pathway for CD154-mediated infl ammation. Indeed, inhi bition of this novel CD154 binding partner significantly attenuates leukocyte accumulation at sites of infl ammation and reduces atherogenesis, indicating that CD154 may promote, at least in part, atherosclerotic lesions in a αMβ2-dependent manner. Th is hypothesis was recently demonstrated in an elegant study showing that specifi c targeting of this dyad with small inhibitory peptides signifi cantly reduces atherogenesis and infl amma tory cell recruitment, but does not aff ect thrombosis and immunity [23] . Th ese data imply that CD154/αMβ2 interactions play a specifi c role in infl ammatory-driven diseases in which leukocyte recruitment and infi ltration at the sites of lesions represent important hallmarks of disease initiation. Specifi c targeting of this interaction has now emerged as a potential treatment strategy against infl ammatory diseases, as compared with global CD154 inhibition where immunodefi ciency and bleeding complications could be observed.
Role of CD154 in rheumatoid arthritis
RA is an autoimmune condition belonging to the rheumatic infl ammatory diseases, and is characterized by chronic infl ammation of the synovial lining of joints. RA implicates many immune and infl ammatory cells including lymphocytes, neutrophils, mast cells, and synovial tissue cells them selves [24] . Figure 2 illustrates the biological signifi cance of CD154 in RA and RA-related atherosclerosis. RA patients exhibit increased expression of CD154 on many vascular and synovial cell types. Indeed, CD4 + T cells, which are involved in cytokine and MMP production in the synovial fl uid of RA patients, Binding of CD154 to its classical CD40 counter-receptor regulates numerous critical biological responses. These mainly include B-cell-dependent isotype switching, cell-mediated immunity (production of cytokines, chemokines, adhesion molecules, growth factors, matrix metalloproteinases and procoagulants) and apoptosis. We have also shown that this interaction regulates platelet activation and thrombosis. The interaction of CD154 with the αIIbβ3 platelet integrin is involved in thrombus stabilization and may provide a novel outside-in signaling pathway by which platelets can be activated. CD154 can also bind to the inactive conformation of α5β1, and this interaction was shown to induce activation of the human monocytic U937 cell line. Finally, αMβ2 can mediate CD154-dependent infl ammatory responses; in particular, leukocyte adhesion and neointimal formation. The pathophysiological relevance of these novel CD154-mediated interactions in infl ammation remains elusive and additional studies will be required to address this issue.
were shown to exhibit upregulation of cell surface CD154 [25] . In addition, by interacting with its CD40 receptor on B cells, CD154 was reported to mediate B-cell survival and production of rheumatoid factor (RF), an important mediator in RA [26] . Further immune-infl ammatory functions of CD154 include the release of cytokines/ chemokines, the produc tion of MMPs and the upregulation of adhesion mole cules in other cell types known to play critical roles in the pathogenesis of RA -namely, synovial monocytes/macro phages, fi broblasts and articular chondrocytes [27] .
Data from RA animal models convincingly support the role of CD154 in the pathogenesis of the disease, as anti-CD154 treatment was shown to attenuate infl ammatory events and disease severity [28] . Moreover, administration of agonistic anti-CD40 antibodies in mice exacerbates disease progression and IFNγ production by T cells [15] . Gene silencing of CD40 through siRNA targeting prevents the development of the disease in mice, further supporting the contribution of CD40 in the pathogenesis of RA [16] . Th e importance of the CD154 axis in RA is also highlighted by the levels of sCD154 found in patients, which correlate with disease severity and both IgM-RF and IgG-RF titers [29] . Interestingly, in a casecontrol cohort study in Spanish females, an association between RA and a specifi c allele variant within the CD154 gene was established. Indeed, authors found that patients with RA express lower frequencies of the 24CAs allele than control patients, thereby linking the CD154 system to RA risk [30] .
Role of CD154 in atherosclerosis
Atherosclerosis is a chronic disease of the vessels involving many infl ammatory and immune events. In the Immune cells in circulation infi ltrate the synovial cavity, where they participate directly in the pathogenesis of rheumatoid arthritis (RA). CD154 expressed on activated T cells and activated platelets (mCD154) or released as a soluble form (sCD154) interacts with CD40 on synovial cells such as B cells, monocytes/macrophages and synovial fi broblasts, as well as with articular chondrocytes. The resulting CD154-mediated responses include release of cytokines, production of matrix metalloproteinases (MMPs) and upregulation of adhesion molecules, all of which enhance the development of RA. On the contrary, increased levels of sCD154 and mCD154 in the vasculature may also contribute to atherosclerotic events by activating vascular cells and inducing the expression of adhesion molecules and the production of cytokines, chemokines, MMPs, and tissue factor. RF, rheumatoid factor. presence of proper risk factors and infl ammatory stimuli, the initial atherosclerotic lesion can develop into a growing fi brous plaque prone to rupture. If left untreated, plaque rupture may ensue, leading to thrombo infl ammatory reactions and vascular complications such as acute coronary syndromes, cerebrovascular diseases and others [31] . Accumulating evidence indicates that CD154 is implicated in all stages of the pathogenesis of atherosclerosis since targeting of this molecule by both pharmacological and genetic approaches signifi cantly reduces the size and lipid contents of atherosclerotic lesions [32, 33] .
In the initial steps, CD154 is involved in endothelial cell activation, a critical step of atherogenesis initiation. CD154-dependent activation of endothelial cells induces expression of adhesion molecules and production of cytokines, which result in the recruitment and infi ltration of infl ammatory cells into the subendothelial space. Th ereafter, CD154 further amplifi es the infl ammatory response by inducing additional cytokine release, produc tion of MMPs and expression of tissue factor in cells of the growing atherosclerotic lesion, mainly macrophages and smooth muscle cells. Th ese CD154-mediated cellular responses contribute to plaque instability and vulnerability to rupture, thereby initiating thrombotic events and clinical manifestations [31] .
CD154 has therefore emerged as an independent and strong risk factor for atherosclerosis. Indeed, enhanced levels of sCD154 have been linked to acute coronary syndromes and correlate with disease prognosis [34] . In addition, CD154 may be involved in the thrombotic events that follow atherosclerotic plaque rupture. In this regard, we have shown that sCD154 primes and enhances agonist-induced activation and aggregation of human platelets through a CD40-mediated TNF receptorassociated factor-2/Rac1/p38 mitogen-activated protein kinase-dependent pathway, which ultimately leads to platelet shape change and actin polymerization. Moreover, we have demonstrated that enhanced levels of sCD154 exacer bate thrombus formation and leukocyte infi ltration in response to vascular injury, in a CD40dependent manner [35] . More recently, we demonstrated that the CD154/CD40 axis triggers NF-κB activation in platelets. Th is signaling pathway plays a critical role in platelet activation and aggregation upon sCD154 stimulation and may represent an important target against athero throm bosis [36] .
Rheumatoid arthritis and vascular risk
RA patients were shown to exhibit increased mortality associated with atherosclerosis compared with the general population [3, 37] . Th e cardiovascular risk even precedes the formal American College of Rheumatology criteria-based diagnosis of RA, indicating an early association between both complications [38] . Moreover, disease severity directly correlates with the risk of develop ing vascular complications, since more advanced disease states seem to predict greater cardiovascular morbidity in RA patients [3] .
Given the immunoinfl ammatory nature of atherosclerosis, interest has been focused on the association between infl ammatory autoimmune diseases and vascular events. Indeed, cardiovascular complications have been described in RA, systemic lupus erythematosus, ankylosing spondylitis, psoriasis, primary anti-phospholipid syndrome, systemic sclerosis or scleroderma and other disorders of infl ammatory nature [39] . Various stages of atherosclerosis, ranging from preclinical events to disease manifestations and complications, have been described in patients with RA. Endothelial dysfunction, the initial step in the development of atherosclerotic lesions, is detected early in RA patients, as indicated by impaired fl ow-mediated dilation. In longer disease durations, more structural damage is observed in the arteries, as measured by increased common carotid intima/media thickness [40] . RA severity has been associated with prevalence and extent of calcifi ed lesions in coronary arteries [41] . Interestingly, a signifi cant interaction was found between many atherosclerotic risk factors and RA parameters, suggesting a synergy between RA modulators and these traditional risk factors in the development and/or acceleration of atherosclerosis [42] .
Common risk factors of rheumatoid arthritis and atherosclerosis
RA and atherosclerosis share a number of risk factors (Table 1) . Smoking, which represents a major atherogenic risk factor, was also found to be associated with RA severity and prognosis in patients harboring the HLA-DR shared epitope or in patients positive for anti-citrullinated protein antibodies (ACPA), two critical biomarkers of RA [43, 44] . Interestingly, the RA susceptibility HLA-DR gene was shown to correlate with cardiovascular events in RA patients, especially if combined with smoking and the presence of high autoantibody levels [45] . Other proatherogenic factors -including diabetes mellitus, upregulated levels of lipokines such as resistin and leptin, and decreased production of the antiinfl ammatory factor adiponectin -are also exhibited in RA patients [46, 47] . In addition to these common risk factors, RA and atherosclerosis share a number of underlying mechanisms of autoimmune and infl am matory nature.
Autoantibodies in rheumatoid arthritis and atherosclerosis
Autoimmune manifestations are the hallmark features of RA and are now increasingly reported in patients with atherosclerotic events. RF and ACPA are the main autoimmune antibodies present in RA. RF is directed against the Fc portion of IgGs, while ACPA are directed against fi brin, fi brinogen and vimentin post-trans lationally modifi ed to contain the amino acid citrulline [48] .
Even though RF can be detected in other diseases or in healthy individuals, it remains an important marker of RA in terms of diagnostic support and evaluation of disease progression risk [49, 50] . Moreover, anti-cyclic citrullinated peptide antibodies have also emerged as reliable diagnostic markers of early RA-associated events and can be used as sensitive test substrates for detecting ACPA in patients [51] . Notably, anti-cyclic citrullinated peptide antibodies have been previously associated with subclinical atherosclerosis in patients with RA, indicating that they may represent important risk factors in the development of accelerated cardiovascular events in these patients [52] .
Other autoimmune antibodies present at high levels in RA include anti-RA33 directed against heterogeneous nuclear ribonucleoprotein A 2 , anti-collagen directed against collagen II and antibodies directed against heat shock proteins (HSPs) [48] . On the contrary, atherosclerosis was also shown to be associated with a number of self-antigens, including oxidized low-density lipoprotein, β 2 -glycoprotein I, as discussed below, and HSP60/65 [53, 54] . Interestingly, immunizing atherosclerosis-prone animals with the HSP60 autoantigen or infusion of lymphocytes directed against this particular antigen was shown to enhance disease progression.
Auto-HSP60 antibodies are also detected in sera of patients with RA [55] . Generation of autoantibodies in RA could therefore be implicated in enhancing atherosclerotic events in patients suff ering with this disease.
Infl ammation in rheumatoid arthritis and atherosclerosis
In addition to their shared autoimmune manifestations, RA and atherosclerosis are also interrelated through their tight infl ammatory nature. Indeed, both disease conditions are characterized by T-cell and macrophage activation. In addition, patients with RA exhibit an upregulation of the infl ammatory marker C-reactive protein, a strong biomarker of cardiovascular risk. Proinfl ammatory cytokines, including TNFα, IL-1, IL-6 and IFNγ, and chemokines such as monocyte chemoattractant protein-1 were also shown to be involved in the pathophysiology of RA and atherosclerosis [31, 56] . Moreover, both diseases show an upregulation of endothelial and immune cell adhesion molecules, as well as an increased production and activity of MMPs [31, 56] .
CD154 as an atherosclerotic risk factor in rheumatoid arthritis
Because of its signifi cant role in the pathology of atherosclerosis and autoimmune conditions such as RA, CD154 could represent an important link between both conditions by contributing to the increased prevalence of vascular diseases seen in RA patients. CD154, both soluble and membrane bound, is upregulated in the synovial cavity of RA patients and could therefore initiate vascular infl ammatory events or, at the least, enhance an already established vascular abnormality ( Figure 2 ). Evidence that CD154 may be linked to vascular complications in RA patients was initially provided by a study assessing levels of sCD154 in RA and rheumatoid vasculitis, which is characterized by extra-articular infl am mation of small and medium-sized blood vessels. Authors found that levels of sCD154 were signifi cantly higher in RA patients who had vasculitis than those without, indicating that CD154 may represent an important etiological factor of vascular infl ammatory development in these patients [29] . Moreover, in a study aiming at investigating the association between RA and atherosclerotic events by assessing platelet, endothelial and coagulation activation markers, serum levels of sCD154 were signifi cantly increased in RA patients as compared with controls [57] .
Because sCD154 in circulation is mainly released from activated platelets, it is regarded as an important marker of platelet activation. Th e above fi ndings may explain, at least in part, the mechanisms by which platelets contribute to both atherosclerosis and RA (Figure 3) . Indeed, platelets have been shown to play an important role in the pathophysiology of RA, although the precise underlying mechanisms remain unknown. Patients with RA were shown to present with increased levels of circulating platelet microparticles, which originate from the shedding of platelet plasma membranes. Th ese patients also exhibit an upregulation of platelet activation markers, including sCD154 [58] . Moreover, Boilard and colleagues observed the presence of platelet microparticles in joint fl uids of patients with RA [59] . Th e formation of these platelet microparticles was dependent upon the recruitment of platelets within the lining of the synovial cavity via the collagen-specifi c GPVI receptor and their interaction with fi broblast-like cells. Reciprocally, platelet microparticles can stimulate fi broblast-like cells to induce the release of cytokines (IL-6) and chemokines (IL-8) of crucial importance in RA pathology [59] . More recently, the same authors also outlined a role for platelets themselves rather than their microparticles in the pathology of infl ammatory arthritis via a fi broblastinduced production of prostacyclin [60] . However, these studies did not investigate the possible contribution of platelet CD154 in the pathology of RA, as synovial fi broblasts express the CD154 receptor, CD40 [8] . Nevertheless, these fi ndings provide important evidence for the existing link between infl ammatory vascular eff ectors such as platelets and their mediators (CD154 perhaps) and autoimmune pathophysiology.
Recently, a polymorphism in the CD40 gene was found to be associated with atherothrombotic manifestations in RA patients, thereby supporting the implication of this axis in the development of accelerated vascular complications in RA [61] . Additional evidence for the contribution of the CD154 axis in the association between RA and atherosclerosis was also described in a study showing that abrogating vasoactive factors such as angiotensin II can aff ect vascular function and infl ammatory markers in RA patients. Th e authors demonstrate that inhibiting the angiotensin-converting enzyme in RA patients amelior ates arterial endothelial function and downregu lates plasmatic levels of soluble CD40 and TNFα [62] . Downregulation of these critical infl ammatory molecules may represent the underlying mechanism by which vascular functions are signifi cantly improved in RA patients treated with angiotensin-converting enzyme inhibitors.
Conclusion
Growing evidence favors the implication of CD154 in the cross-talk between autoimmune diseases and atherosclerosis, contributing as such to the enhancement of vascular abnormalities in these conditions. CD154 could therefore represent an interesting target for preventive or therapeutic strategies aiming at decreasing atherosclerotic load in autoimmune diseases. Many traditional, autoimmune and infl ammatory mechanisms have been targeted in the goal of improving vascular functions in patients with autoimmune disorders. Cholesterol-lowering drugs such as statins, also known for their antiinfl ammatory actions, have shown benefi cial anti-infl ammatory eff ects with modifi cation of vascular risk factors in RA patients [63] . Statins also have benefi cial eff ects in reducing RA disease activity itself, consolidating again the notion that both diseases are intimately linked [64] . Inhibition of infl ammatory pathways induced by the vasoactive factor angiotensin II also improves vascular functions in RA patients.
Interestingly, current RA therapies such as TNFα inhibitors (infl iximab, adalimumab and etanercept) have been shown to be eff ective in controlling disease activity, while providing signifi cant benefi ts in the management of vascular complications observed in these patients. For instance, positive eff ects on carotid intima-media thickness, arterial stiff ness and endothelial dysfunction have been reported in RA patients treated with TNF antagonists [65] . However, multiple studies have determined that TNF blockage increases total cholesterol levels (triglycerides, low-density lipoproteins and high-density lipoproteins) in RA patients, putting in doubt the level of effi cacy of these treatments in reducing cardiovascular events in patients with autoimmune diseases such as RA [65] . Moreover, nonsteroidal anti-infl ammatory drugs such as cyclooxygenase-2 inhibitors for the treatment of RA have been associated with an increased risk of developing cardiovascular events, indicating that these agents may not represent a suitable therapeutic option for decreasing atherosclerotic load in these patients [66] . Platelets and platelet microparticles (PMPs) have been shown to contribute to both rheumatoid arthritis (RA) and atherosclerotic development. The vast majority of soluble CD154 (sCD154) found in circulation originates from activated platelets and this platelet infl ammatory mediator may represent the biological link between both complications. Enhanced levels of sCD154 correlate with RA disease severity, as well as acute coronary syndromes (ACS). Moreover, a positive feedback loop between RA activity and sCD154 and platelets may take place, whereby disease initiation and progression can reciprocally exacerbate platelet activation and sCD154 levels, leading to atherosclerotic development and vascular complications. As common denominators to both complications, platelets and their release of sCD154 may represent pivotal contributors to atherogenesis initiation in RA patients.
Because of its critical role as a common factor in the pathogenesis of atherosclerosis and autoimmune diseases, blocking CD154 interactions may show benefi cial results in the treatment of vascular complications associated with autoimmune diseases or in the treatment of autoimmune diseases themselves. Unfortunately, direct clinical evidence for the role of CD154 as a contributor to accelerated vascular complications in RA patients has been hindered by the fact that pre-existing trials using anti-CD154 antibodies induce thromboembolic complica tions in treated patients, perhaps through unwanted Fc activation at the surface of platelets [67] . Th ese side eff ects have impeded the continuation of ongoing trials, and no clinical data on the eff ect of anti-CD154 therapy on the occurrence of vascular complications in autoimmune patients have been provided. Further studies will be necessary to fully establish the role of CD154 in the development of accelerated cardiovascular events in RA patients. Th e development of novel anti-CD154 agents may render better clinical outcomes, while providing affi rmation of this axis as a linker of autoimmune diseases and cardiovascular complications.
